Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
ZN ZNTL Zentalis Pharmaceuticals, Inc. FY ended Mar 20, 2026 | $3.80 | $272.35M | $298.14M | $67.43M | -$136.62M | -$137.06M | -1.99x | 4.04x | — |
BP BPMC Blueprint Medicines Corp FY ended Feb 11, 2025 | — | — | — | $508.82M | $23.69M | -$67.09M | — | — | — |
JA JAZZ Jazz Pharmaceuticals plc FY ended Apr 15, 2026 | $244.54 | $15.87B | $18.75B | $4.27B | $69.38M | -$356.15M | -41.87x | 3.72x | 58.20x |
SR SRPT Sarepta Therapeutics, Inc. FY ended Feb 24, 2026 | $20.86 | $2.20B | $2.78B | $2.20B | -$686.34M | -$713.41M | -2.93x | 1.00x | — |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 45.55x | 1/4 | -$4.61B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 2.92x | 3/4 | $638.74M | $6.62 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -15.60x | 3/4 | $1.77B | $18.38 | Peer averages are not economically meaningful for this method. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
ZN ZNTL Zentalis Pharmaceuticals, Inc. FY ended Mar 20, 2026 | $3.80 | $272.35M | $298.14M | $67.43M | -$136.62M | -$137.06M | -1.99x | 4.04x | — |
BP BPMC Blueprint Medicines Corp FY ended Feb 11, 2025 | — | — | — | $508.82M | $23.69M | -$67.09M | — | — | — |
JA JAZZ Jazz Pharmaceuticals plc FY ended Apr 15, 2026 | $244.54 | $15.87B | $18.75B | $4.27B | $69.38M | -$356.15M | -41.87x | 3.72x | 58.20x |
SR SRPT Sarepta Therapeutics, Inc. FY ended Feb 24, 2026 | $20.86 | $2.20B | $2.78B | $2.20B | -$686.34M | -$713.41M | -2.93x | 1.00x | — |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 45.55x | 1/4 | -$4.61B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 2.92x | 3/4 | $638.74M | $6.62 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -15.60x | 3/4 | $1.77B | $18.38 | Peer averages are not economically meaningful for this method. |
